Skip to main content

Advocacy

FDA Food and Drug Admin Logo
FDA Workshop: Opportunities to Improve Dose Optimization: Designing Trials and Applying Pharmacometrics Advocacy

FDA Workshop: Opportunities to Improve Dose Optimization: Designing Trials and Applying Pharmacometrics

*May 2022* EGFR Resisters co-founder Jill Feldman participated as a panelist in this FDA Oncology Workship:  3a "Opportunities to Improve Dose Optimization: Designing Trials and Applying Pharmacometrics; and 3b "Opportunities to Improve Dose Optimization: Assessing Safety and Tolerability." Current strategies for determining the recommended dose(s) of anticancer agents for evaluation…
American Lung Association logo
What Can you Expect from a Lung Cancer Clinical Trial AdvocacyResearchTreatments

What Can you Expect from a Lung Cancer Clinical Trial

*November 2021* In this webinar, Dr. Mark A. Socinski, Executive Medical Director, Advent Health Cancer Institute, Orlando, FL, will explain the process of participating in a lung cancer clinical trial from beginning to end. Dr. Socinski will explain how typical lung cancer clinical trials are structured, how patients are monitored…
laurabbook@gmail.com
December 7, 2021
ASTRO Org
Advancing Person-Centered Care Through Innovation AdvocacyResearchTreatments

Advancing Person-Centered Care Through Innovation

*November 2021*   Listen to EGFR Resisters co-founder Jill Feldman's presentation at ASTRO — innovating for clinically meaningful benefits that matter to patients. The final session of the symposium was a lively debate on randomized clinical trials versus real world data. Four speakers offered points/counterpoints for randomized clinical trials versus…
laurabbook@gmail.com
November 12, 2021